Abstract
Background: Arterial hypertension (AH) and peripheral arterial disease (PAD) frequently coincide. While significant attention is paid to AH, PAD is often underestimated. It is known that both AH and PAD present high cardiovascular risks for ischemic events. To date, the use of the most common anti-hypertensive drugs in PAD patients is still under debate.
Methods: Data from studies of large populations and minor cohorts of patients show AH and PAD together or PAD alone. Results: cardiovascular and renal outcomes for PAD patients show lowered arterial pressure. We cannot rank the class of anti-hypertensive drugs recommended for PAD patients with AH. However, optimum targeted anti-hypertensive therapy is strongly recommended by cardiology guidelines.
Conclusion: comprehensive cardiovascular protection is the most important goal in using anti-AH drugs in PAD together with other drugs such as anti-platelets and statins.
Keywords: Arterial hypertension, peripheral arterial disease, cardiovascular risks, anti-hypertensive drugs, arterial pressure, anti-hypertensive therapy.
Current Pharmaceutical Design
Title:How to Treat Patients with Essential Hypertension and Peripheral Arterial Disease
Volume: 23 Issue: 31
Author(s): Salvatore Santo Signorelli*
Affiliation:
- Department of Clinical and Experimental Medicine, University of Catania; General Medicine Division, University Hospital “G.Rodolico. Catania,Italy
Keywords: Arterial hypertension, peripheral arterial disease, cardiovascular risks, anti-hypertensive drugs, arterial pressure, anti-hypertensive therapy.
Abstract: Background: Arterial hypertension (AH) and peripheral arterial disease (PAD) frequently coincide. While significant attention is paid to AH, PAD is often underestimated. It is known that both AH and PAD present high cardiovascular risks for ischemic events. To date, the use of the most common anti-hypertensive drugs in PAD patients is still under debate.
Methods: Data from studies of large populations and minor cohorts of patients show AH and PAD together or PAD alone. Results: cardiovascular and renal outcomes for PAD patients show lowered arterial pressure. We cannot rank the class of anti-hypertensive drugs recommended for PAD patients with AH. However, optimum targeted anti-hypertensive therapy is strongly recommended by cardiology guidelines.
Conclusion: comprehensive cardiovascular protection is the most important goal in using anti-AH drugs in PAD together with other drugs such as anti-platelets and statins.
Export Options
About this article
Cite this article as:
Signorelli Santo Salvatore*, How to Treat Patients with Essential Hypertension and Peripheral Arterial Disease, Current Pharmaceutical Design 2017; 23 (31) . https://dx.doi.org/10.2174/1381612823666170608083605
DOI https://dx.doi.org/10.2174/1381612823666170608083605 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Small Molecule Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Non Small Cell Lung Cancer Treatment
Current Cancer Therapy Reviews 58-Year Old Men with Non-Stenotic Carotid Artery Plaques and the Relationship with Cardiovascular Risk Factors and Future Cardiovascular Events
Vascular Disease Prevention (Discontinued) Cardiac Effects of HDL and Its Components on Diabetic Cardiomyopathy
Endocrine, Metabolic & Immune Disorders - Drug Targets Mycophenolate Mofetil for the Treatment of Systemic Sclerosis
Letters in Drug Design & Discovery Fenoldopam Mesylate: A Narrative Review of Its Use in Acute Kidney Injury
Current Pharmaceutical Biotechnology Mononuclear Cell Recruitment and Inflammation in Atherosclerosis
Vascular Disease Prevention (Discontinued) Role of Polymorphisms in Factor V (FV Leiden), Prothrombin, Plasminogen Activator Inhibitor Type-1 (PAI-1), Methylenetetrahydrofolate Reductase (MTHFR) and Cystathionine β-Synthase (CBS) Genes as Risk Factors for Thrombophilias
Mini-Reviews in Medicinal Chemistry Arterial Hyperoxia in Severe Head Injury: A Useful or Harmful Option?
Current Pharmaceutical Design A Comprehensive Literature Search: Drugs as Possible Triggers of Takotsubo Cardiomyopathy
Current Clinical Pharmacology Allosteric Inhibition of G-Protein Coupled Receptor Oligomerization: Strategies and Challenges for Drug Development
Current Topics in Medicinal Chemistry Renal Phosphate Handling in Antiretroviral-naive HIV-Infected Patients
Infectious Disorders - Drug Targets NGS of microRNAs Involved in Cardioprotection Induced by Sevoflurane Compared to Propofol in Myocardial Revascularization Surgery: The ACDHUVV-16 Clinical Trial
Current Medicinal Chemistry ACKNOWLEDGEMENTS TO THE REVIEWERS
Current Hypertension Reviews Pulmonary Hypertension: Clinical Presentation, Diagnosis, Treatment,and Dana Point World Symposium Highlights
Current Respiratory Medicine Reviews Nitric Oxide Therapies in Vascular Diseases
Current Pharmaceutical Design Synthesis of Novel Hydrazone Derivatives of 2, 5-difluorobenzoic Acid as Potential Antibacterial Agents
Letters in Drug Design & Discovery From The Editors Perspective: Unlocking the Secrets to Cell Survival and Longevity
Current Neurovascular Research Medicinal Properties of the Jamaican Pepper Plant Pimenta dioica and Allspice
Current Drug Targets Recent Advances in Pathophysiology of Traumatic Brain Injury
Current Neuropharmacology Hypoglycemic Hemiparesis Masquerading As Ischemic Stroke: When Guideline Fails
Current Drug Therapy